Newamsterdam Pharma CO NV Form 4 insider transactions

Louise Frederika Kooij, Chief Accounting Officer of NewAmsterdam Pharma Co N.V., reports the acquisition of 15,000 restricted stock units.

Michael Davidson, CEO of NewAmsterdam Pharma, reports acquiring restricted stock units and options, signaling changes in his beneficial ownership of the company's securities.

Johannes Jacob Pieter Kastelein, Chief Scientific Officer of NewAmsterdam Pharma, was granted 34,000 restricted stock units on January 7, 2025.

Juliette Berangere Audet, Chief Business Officer of NewAmsterdam Pharma Co N.V., reports the acquisition of 14,000 ordinary shares through restricted stock units.

William A. Jones, Jr., Chief Commercial Officer of NewAmsterdam Pharma Co N.V., was granted 43,000 restricted stock units (RSUs) on January 7, 2025, which will vest over three years.

NewAmsterdam Pharma's Chief Operating Officer, Douglas F. Kling, was granted 44,000 restricted stock units on January 7, 2025.

NewAmsterdam Pharma's Chief Financial Officer, Mayur Ian Somaiya, was granted 38,000 restricted stock units on January 7, 2025.

NewAmsterdam Pharma's Chief Operating Officer, Douglas F. Kling, was granted options to purchase 250,000 ordinary shares, vesting over four years.

Louise Frederika Kooij, Chief Accounting Officer of NewAmsterdam Pharma Co. N.V., acquired 80,000 stock options on January 2, 2025.

Juliette Berangere Audet, Chief Business Officer of NewAmsterdam Pharma, was granted options to purchase 100,000 ordinary shares.

Mayur Ian Somaiya, CFO of NewAmsterdam Pharma Co N.V., reports the acquisition of options to purchase 220,000 ordinary shares.

William A. Jones, Jr., Chief Commercial Officer of NewAmsterdam Pharma Co N.V., reports the acquisition of options to purchase 200,000 ordinary shares.

Johannes Jacob Pieter Kastelein, Chief Scientific Officer of NewAmsterdam Pharma, was granted options to purchase 200,000 ordinary shares.

Forbion Growth Opportunities Fund I Cooperatief U.A. and Forbion Capital Fund IV Cooperatief U.A., through ForGrowth NAP B.V., sold 29,846 ordinary shares of NewAmsterdam Pharma Co N.V. under a pre-arranged Rule 10b5-1 trading plan.

Forbion-affiliated entities, including ForGrowth NAP B.V., Forbion Capital Fund IV Cooperatief U.A., and Forbion Growth Opportunities Fund I Cooperatief U.A., executed sales of NewAmsterdam Pharma Co N.V. ordinary shares on December 26 and 27, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Forbion Growth Opportunities Fund I Cooperatief U.A. and Forbion Capital Fund IV Cooperatief U.A., through related entities, have sold a portion of their NewAmsterdam Pharma Co N.V. shares on the open market between December 20 and December 24, 2024, pursuant to a pre-arranged Rule 10b5-1 trading plan.

ForGrowth NAP B.V., a significant shareholder of NewAmsterdam Pharma Co N.V., executed multiple sales of ordinary shares between December 18 and December 19, 2024, under a pre-arranged trading plan.

Forbion-affiliated entities executed multiple sales of NewAmsterdam Pharma Co N.V. ordinary shares between December 16 and December 17, 2024, reducing their overall holdings.

Bain Capital Life Sciences entities have acquired pre-funded warrants to purchase over 1.6 million ordinary shares of NewAmsterdam Pharma Co N.V.

Forbion Capital funds have sold a portion of their NewAmsterdam Pharma holdings through a pre-arranged trading plan, reducing their overall stake.

Forbion Capital funds have sold a portion of their NewAmsterdam Pharma holdings over several days, reducing their overall stake.

Forbion Capital funds executed pre-planned sales of NewAmsterdam Pharma shares, reducing their holdings slightly.

Forbion Capital funds executed pre-planned sales of NewAmsterdam Pharma shares, reducing their holdings slightly.

Michael H. Davidson, CEO of NewAmsterdam Pharma Co N.V., reports the acquisition of 15,000 warrants exercisable for ordinary shares.

Chief Accounting Officer Louise Kooij reports acquisition and disposal of NewAmsterdam Pharma Co N.V. shares.

Juliette Berangere Audet, Chief Business Officer of NewAmsterdam Pharma Co N.V., reports a transaction involving ordinary shares.

NewAmsterdam Pharma's CEO, Michael H. Davidson, recently purchased 5,000 ordinary shares of the company, increasing his direct holdings.

Mark C. McKenna, a director of NewAmsterdam Pharma Co N.V., acquired options to purchase 72,500 ordinary shares on July 17, 2024.

NewAmsterdam Pharma's CEO, Michael H. Davidson, recently acquired 5,000 ordinary shares of the company at an average price of $17.2617 per share.

Juliette Berangere Audet, Chief Business Officer of NewAmsterdam Pharma Co N.V., received stock options for 250,000 ordinary shares following her appointment.